According to the company’s chief executive, Serum Institute Of India has applied to the country’s drug regulator and the health ministry for full approval of its Covid-19 vaccine Covishield.
More than 1.25 billion doses of AstraZeneca’s Covid-19 vaccine, branded as Covishield, have been given in India by Serum Institute.
According to Serum Institute CEO Adar Poonawalla, the Indian government now has enough data to consider a full approval.
At the start of the year, Serum Institute, the biggest vaccine maker, received approval for the emergency use of Covishield in India.
Covishield and Bharat Biotech’s inactivated vaccine Covaxin has dominated the country’s vaccination campaign so far in this.
According to Poonawalla, Serum Institute has nearly quadrupled its monthly capacity of AstraZeneca’s shots to as many as 240 million doses and is ready to export “large volumes” starting in January.
